TY - JOUR
T1 - Multiparameter flow cytometric analysis reveals low percentage of bone marrow hematogones in myelodysplastic syndromes
AU - Maftoun-Banankhah, Sepideh
AU - Maleki, Atousa
AU - Karandikar, Nitin J.
AU - Arbini, Arnaldo A.
AU - Fuda, Franklin S.
AU - Wang, Huan You
AU - Chen, Weina
PY - 2008/2
Y1 - 2008/2
N2 - Diagnosis of myelodysplastic syndromes (MDS) could be difficult. We explored the usefulness of the enumeration of maturing B-lineage precursors (hematogones) by multiparameter flow cytometric analysis in the diagnosis of MDS in bone marrow (BM) specimens. We evaluated 111 MDS, 120 non-MDS (most with cytopenias; control group 1), and 41 noncytopenic lymphoma staging BM (control group 2) specimens. The percentage of total hematogones was significantly lower in MDS (median, 0%; mean, 0.10%) compared with non-MDS (control group 1, median, 0.38%, and mean, 0.91%; control group 2, median, 0.38%, and mean, 0.60%; P < .0001), as was the percentage of the most immature (stage I) hematogones. Thus, hematogone enumeration may serve as a biomarker to aid in the diagnosis of MDS. Interestingly, the percentage of hematogones was not significantly different between MDS subgroups or patients with MDS with and without chromosomal abnormalities, implying that a defect in maturing B-cell precursors may be an early event in the pathogenesis of MDS.
AB - Diagnosis of myelodysplastic syndromes (MDS) could be difficult. We explored the usefulness of the enumeration of maturing B-lineage precursors (hematogones) by multiparameter flow cytometric analysis in the diagnosis of MDS in bone marrow (BM) specimens. We evaluated 111 MDS, 120 non-MDS (most with cytopenias; control group 1), and 41 noncytopenic lymphoma staging BM (control group 2) specimens. The percentage of total hematogones was significantly lower in MDS (median, 0%; mean, 0.10%) compared with non-MDS (control group 1, median, 0.38%, and mean, 0.91%; control group 2, median, 0.38%, and mean, 0.60%; P < .0001), as was the percentage of the most immature (stage I) hematogones. Thus, hematogone enumeration may serve as a biomarker to aid in the diagnosis of MDS. Interestingly, the percentage of hematogones was not significantly different between MDS subgroups or patients with MDS with and without chromosomal abnormalities, implying that a defect in maturing B-cell precursors may be an early event in the pathogenesis of MDS.
KW - Cytogenetics
KW - Hematogones
KW - Multiparameter flow cytometry
KW - Myelodysplastic syndromes
UR - http://www.scopus.com/inward/record.url?scp=40449134575&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=40449134575&partnerID=8YFLogxK
U2 - 10.1309/4W2G3NDXUPG5J33N
DO - 10.1309/4W2G3NDXUPG5J33N
M3 - Article
C2 - 18208811
AN - SCOPUS:40449134575
SN - 0002-9173
VL - 129
SP - 300
EP - 308
JO - American journal of clinical pathology
JF - American journal of clinical pathology
IS - 2
ER -